Professor Ira Shoulson
Non-Executive Director, Professor of Neurology, Pharmacology and Human Science, Georgetown University, Washington
Prof. Ira Shoulson was appointed as a director of our company on May 13, 2014. Professor Shoulson is Professor of Neurology, Pharmacology and Human Science at Georgetown University, Washington, DC, USA, and Director of the University’s Program for Regulatory Science and Medicine (PRSM).
Professor Shoulson is the Chairman of our Research and Development Advisory Board and has served as a consultant to, and member of, several FDA advisory committees over the past three decades, and has been involved in eight successful new drug applications to the FDA, notably long-acting methylphenidate (Concerta©) for attention deficit disorder, rasagiline (Azilect©) for Parkinson disease, and tetrabenazine (Xenazine©), the first drug approved by the FDA for the treatment of chorea in Huntington disease (HD). He is also principal investigator of the Georgetown University Center of Excellence in Regulatory Science and Innovation (CERSI), one of four research and education centers currently funded by the FDA.
Prior to taking up his position with our company, Professor Shoulson concluded his elected term as Chair and President of the Huntington Study Group.